Vinay Prasad, M.D., has rejoined the FDA, the latest turn in a monthslong stretch of leadership turnover at the agency. | “At ...

The Food and Drug Administration's polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of biotech executives, patient groups and conservative allies of President ...

Vinay Prasad was reinstated as the head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA) on 11 August. He had resigned on 29 July.1 “At the FDA’s ...

Vinay Prasad has returned to the U.S. Food and Drug Administration as the director of the Center for Biologics Evaluation and Research after a brief departure. Previously appointed in May, Prasad is ...

Vinay Prasad, a former critic of U.S. COVID-19 policies, returns to the FDA's Center for Biologics Evaluation and Research after briefly leaving. His tenure drew criticism, notably over the handling ...

Vinay Prasad has returned to lead the US regulator’s Center for Biologics Evaluation and Research, resuming responsibility ...

Dr Vinay Prasad was appointed as director of the Centre for Biologics Evaluation and Research in May, but he stepped down ...

Vinay Prasad leaves FDA apparently due to backlash from the agency's handling of potential deaths related to Sarepta's Elevidys. Read more here.

Indian-origin scientist Vinay Prasad resigned as the FDA's vaccine and gene therapy chief in just three months after backlash over halting Sarepta's DMD gene therapy on safety grounds. His caution ...

The SPDR® S&P Biotech ETF rebounded over 20% since lows in April, despite changes at the FDA that could have signaled a ...

WASHINGTON, DC – Dr. Vinay Prasad, the polarizing official who led U.S. vaccine oversight under the Trump administration, has stepped down from his position at the Food and Drug Administration ...